Staphylococcus aureus vaccination for dialysis patients - An update

Advances in Renal Replacement Therapy

Volumn 3, Issue 4, 1996, Pages 302-308

  Fattom, A I ^a   Naso, R ^a  

^a NONE   (United States)

Author keywords

dialysis patients; infection; Staphylococcus aureus; vaccination

Indexed keywords

POLYSACCHARIDE;

BACTERIAL INFECTION; BACTERIAL MEMBRANE; DIALYSIS; HEMODIALYSIS; IMMUNIZATION; MORBIDITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; VACCINATION;

EID: 0029907947     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1073-4449(96)80009-4     Document Type: Article

References (57)

1. JN Sheagren Staphylococcus aureus: The persistent pathogen N Engl J Med 310 1984 1368 1373
2. VL Yu A Goetz M Wagener Staphylococcus aureus nasal carriage and infection in patients on hemodialysis N Engl J Med 315 1986 91 96
3. LG Kaplowitz JA Comstock DM Landwehr Prospective study of microbial colonization of the nose and skin and infection of vascular access site in hemodialysis patients J Clin Microbiol 26 1988 1257 1262
4. B Piraino A review of Staphylococcus aureus exit-sit and tunnel infections in peritoneal dialysis patients Am J Kidney Dis 16 1990 89 95
5. B Piraino J Bernardini M Sorkin A five-year study of the microbiologic results of exit site infections and peritonitis in continuous ambulatory peritoneal dialysis Am J Kidney Dis 10 1987 281 286
6. SH Cohen MM Morita M Bradford A seven-year experience with methicillin-resistant Staphylococcus aureus Am J Med 91 suppl 3B 1991 233 237
7. RC Moellering Emergence of Enterococcus as a significant pathogen Clin Infect Dis 14 1992 1173 1178
8. SAN Tailor EM Bailey MJ Rybak Enterococcus, an emerging pathogen Ann Pharm 27 1993 1231 1234
9. WC Noble Z Virani RGA Cree Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to S. aureus FEMS Microbiol lett 93 1992 195 198
10. RM Krause Dynamics of emergence J Infect Dis 170 1994 265 271
11. TJ Foster Potential for vaccination against infections caused by S. aureus Vaccine 9 1991 221 227
12. JB Robbins R Schneerson WB Egan Virulence properties of bacterial capsular polysaccharides: Unanswered questions H Smith JJ Skehel MJ Turner The Molecular Basis of Microbial Pathogenicity 1980 Verlag Chemie GmbH Weinheim 115 132
13. JB Robbins R Austrian CJ Lee Considerations for formulating the second generation pneumococcal vaccine with the emphasis of the cross-reactive types within groups J Infect Dis 148 1983 1136 1159
14. R Austrian Some observations on the pneumococcal vaccine and on the current status of pneumococcal disease and its prevention Rev Infect Dis 3 1981 S51 S57
15. JB Robbins Vaccines for the prevention of encapsulated bacterial diseases: Current status, problems and prospects for the future Immunochemistry 15 1978 839 854
16. MS Bergdoll BA Cross RF Reiser A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Lancet 1 1981 1017 1027
17. N Suttorp E Habben Effect of staphylococcal alphatoxin on intracellular Ca+z in polymorphonuclear leukocytes Infect Immun 56 1988 2228 2234
18. AL Bisno FA Waldvogel Infections Associated with Indwelling Medical Devices 1994 ASM Press Washington, DC
19. T Foster D McDevitt Surface associated protein of Staphylococcus aureus : Their possible roles in virulence FEMS Microbiol Lett 118 1994 199 205
20. CM Bitar CG Mayhall VA Lamb Outbreak due to methicillin and rifampin resistant Staphylococcus aureus: Epidemiology and eradication of the resistant strain from the hospital Infect Control 8 1987 15 23
21. GK Best DF Scott JM Kling Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody Infect Immun 56 1988 998 999
22. PG Quie Bactericidal function of human polymorphonuclear leukocytes Pediatrics 50 1972 264 270
23. S Morse Staphylococci and other micrococci RJ Dubos JG Hirsch Bacterial and Mycotic Infection of Man 1965 Lippincott Philadelphia 412 439
24. GG Salmon Jr M Symonds Staphage lysate therapy in chronic staphylococcal infections J Med Assoc NJ 60 1963 188 193
25. RE Bryant JP Sanford A Alcoze Treatment of recurrent furunculosis with staphylococcal bacteriophagelysed vaccine JAMA 194 1965 11 14
26. H Dillenberg Experience with a polyvalent staphylococcal vaccine with alpha-toxoid Can J Publ Health 53 1962 248 253
27. H Dillenberg MPD Waldron A preventive approach to impetigo of treaty Indiands using a Staphylococcus polyvalent somatic antigen vaccine Can Med Assoc J 89 1963 947 949
28. DE Rogers MA Melly Speculation on the immunology of staphylococcal Infection Ann NY Acad Sci 128 1965 274 284
29. MA Melly LJ Duke DF Liau Biological properties of encapsulated Staphylococcus aureus Infect Immun 10 1974 389 397
30. S Fisher Observation on an antistaphylococcal mouse protective antibody in human sera J Exp Biol 39 1961 413 422
31. JC Lee MJ Betley CA Hopkins Virulence studies in mice of transposon-induced mutant of Staphylococcus aureus differing in capsular size J Infect Dis 156 1987 751 760
32. JC Lee NE Perez CA Hopkins Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection J Infect Dis 157 1988 723 730
33. WW Karakawa JM Fournier WF Vann Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus J Clin Microbiol 22 1985 445 447
34. WW Karakawa WF Vann Capsular polysaccharides of Staphylococcus aureus Semin Infect Dis 4 1982 285 293
35. R Arbeit WW Karakawa WF Vann Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus Diagn Microbiol Infect Dis 2 1984 85 91
36. B Poutrel L Sutra Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses J Clin Microbiol 31 1993 467 469
37. B Poutrel A Boutonnier L Sutra Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk J Clin Microbiol 26 1988 38 40
38. WW Karakawa A Sutton R Schneerson Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes Infect Immun 56 1988 1090 1095
39. A Fattom R Schneerson SC Szu Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A Infect Immun 58 1990 2367 2374
40. A Fattom J Shiloach D Bryla Comparative immunogenicity of conjugates composed of Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridylthio) propionate Infect Immun 60 1992 584 589
41. JB Robbins R Schneerson WF Vann Prevention of systemic infections caused by group B Streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines Ann NY Acad Sci 754 1995 68 82
42. E AlonsoDe Velasco BAT Dekker AFM Verheul Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: Relationships with protection against Streptococcus pneuminiae infection in mice J Infect Dis 172 1995 562 565
43. S Xu R Arbeit CJ Lee Phagocytic killing of encapsulated Staphylococcus aureus by human polymorphonuclear lymphocytes Infect Immun 60 1992 1358 1362
44. AR Albus RD Arbeit CJ Lee Virulence of Staphylococcus aureus mutants altered in type 5 capsules production Infect Immun 59 1991 1008 1014
45. LM Baddour C Lowrance A Albus Staphylococcus aureus microcapsule expression attenuates bacterial virulence in rat model of experimental endocarditis J Infect Dis 165 1992 749 753
46. J Nemeth CJ Lee Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis Infect Immun 63 1995 375 380
47. DP Greenberg JI Ward AS Bayer Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits Infect Immun 55 1987 3030 3034
48. B Poutrel FB Gilbert M Lebrun Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains Clin Diagn Lab Immunol 2 1995 166 171
49. JB Robbins R Schneerson Polysaccharide-protein conjugates A new generation of vaccines. J Infect Dis 161 1990 821 832
50. A Fattom R Schneerson WW Karakawa Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A Infect Immun 61 1993 1023 1032
51. A Fattom J Sarwar A Ortiz Antibodies to capsular polysaccharides are protective against Staphylococcus aureus challenge in mice Interscience Confer Antimicrob Agents and Chemother 35 1995 28 (abstr)
52. JF Dobkin MH Miller NH Steigbigel Septicemia in patients on chronic hemodialysis Ann Intern Med 88 1978 28 33
53. AS Cross RT Steigbigel Infective endocarditis and access site infection in patients on hemodialysis Ann Intern Med 88 1978 28 33
54. A Sciatizzi P Strippoli Prevention of Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis LC Smeby S Jorstad TE Wideroe Immune and Metabolic Aspects of Therapeutic Blood Systems 1986 Basel Karger 191 196
55. LA Poole-Warren MD Hallet PW Hones Vaccination for the prevention of CAPD associated with staphylococcal infections: Results of a prospective multicenter clinical trial Clin Nephrol 35 1991 198 206
56. LA Poole-Warren PC Farrell The role of vaccination in the prevention of staphylococcal peritonitis in continuous ambulatory peritoeal dialysis Perit Dial Int 13 1993 176 177
57. P Welch A Fattom J Moore Safety and immunogenicity of S. aureus type 5 capsular polysaccharidePseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis J Am Soc Nephrol 7 1996 1 7